Publications

  1. Correction to "Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations". J Chem Theory Comput. 2022 Dec 09. Sandoval-Pérez A, Winger BA, Jacobson MP. PMID: 36493348.
  2. Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations. J Chem Theory Comput. 2022 Oct 11; 18(10):6251-6258. Sandoval-Pérez A, Winger BA, Jacobson MP. PMID: 36166736; PMCID: PMC9558371.
  3. Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies. J Chromatogr Open. 2022 Nov; 2. Huang L, Winger BA, Cheah V, Gingrich D, Marzan F, Lu Y, Cooper JC, Aweeka F, Long-Boyle J. PMID: 35875822; PMCID: PMC9302610.
  4. Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation. J Clin Pharmacol. 2022 07; 62(7):873-882. Li S, Dvorak CC, Lu Y, Chan D, Gobburu JVS, Long-Boyle J, Apsel Winger B. . PMID: 35048362.
  5. A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults. Front Pediatr. 2021; 9:713091. Apsel Winger B, Long SE, Brooks J, Gupta AO, Dvorak CC, Long-Boyle JR. PMID: 34350148; PMCID: PMC8326409.
  6. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021 06; 11(6):1424-1439. Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee JA, Gennarini L, Adhav AA, Clinton CM, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Imamovic A, Tognon CE, Patel T, Faust HL, Contreras CF, Cremer A, Cortopassi WA, Garrido Ruiz D, Jacobson MP, Dharia NV, Su A, Robichaud AL, Saur Conway A, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway KA, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier K. PMID: 33563661; PMCID: PMC8178162.
  7. The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders. Transplant Cell Ther. 2021 03; 27(3):258.e1-258.e6. Apsel Winger B, Shukla P, Kharbanda S, Keizer RJ, Goswami S, Cowan MJ, Dvorak CC, Long-Boyle J. PMID: 33781528.
  8. Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population. Front Pharmacol. 2020; 11:888. Shukla P, Goswami S, Keizer RJ, Winger BA, Kharbanda S, Dvorak CC, Long-Boyle J. PMID: 32714184; PMCID: PMC7351521.
  9. Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas. J Clin Pharmacol. 2020 09; 60(9):1209-1219. Wang H, Long-Boyle J, Winger BA, Nicolaides T, Mueller S, Prados M, Ivaturi V. PMID: 32476174.
  10. ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT. Cancer Res. 2019 08 15; 79(16):4283-4292. Apsel Winger B, Cortopassi WA, Garrido Ruiz D, Ding L, Jang K, Leyte-Vidal A, Zhang N, Esteve-Puig R, Jacobson MP, Shah NP. PMID: 31270078; PMCID: PMC6697585.
  11. Mycobacterium bovis Enterocolitis in an Immunocompromised Host. J Pediatr Gastroenterol Nutr. 2016 07; 63(1):e17-9. Winger BA, Foy E, Sud SR, MacKenzie JD, Pua HH, Lau AH, Heyman MB, Laszik Z, Tureen J. PMID: 26020480; PMCID: PMC4449326.
  12. PPARγ: Welcoming the New Kid on the CML Stem Cell Block. Cancer Cell. 2015 Oct 12; 28(4):409-411. Apsel Winger B, Shah NP. PMID: 26461088.
  13. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009 Feb 10; 7(2):e38. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. PMID: 19209957; PMCID: PMC2637922.
  14. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov; 4(11):691-9. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. PMID: 18849971; PMCID: PMC2880455.
  15. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell. 2008 Aug 12; 14(2):180-92. Zunder ER, Knight ZA, Houseman BT, Apsel B, Shokat KM. PMID: 18691552; PMCID: PMC2720137.
  16. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem Biol Drug Des. 2006 May; 67(5):355-63. Mackey ZB, Baca AM, Mallari JP, Apsel B, Shelat A, Hansell EJ, Chiang PK, Wolff B, Guy KR, Williams J, McKerrow JH. PMID: 16784460.
  17. Regulation of metalloproteinases and NF-kappaB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: contrasting effects of nabumetone and 6MNA. Br J Pharmacol. 2004 Jul; 142(6):973-82. Pillinger MH, Dinsell V, Apsel B, Tolani SN, Marjanovic N, Chan ES, Gomez P, Clancy R, Chang LF, Abramson SB. PMID: 15210577; PMCID: PMC1575112.
  18. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J Immunol. 2003 Dec 01; 171(11):6080-9. Pillinger MH, Rosenthal PB, Tolani SN, Apsel B, Dinsell V, Greenberg J, Chan ES, Gomez PF, Abramson SB. PMID: 14634122.